Sotatercept + Placebo + Background PAH Therapy
Phase 3Completed 0 watching 0 views this week📈 Rising
77
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Pulmonary Arterial Hypertension
Conditions
Pulmonary Arterial Hypertension
Trial Timeline
Jan 25, 2021 → Dec 6, 2022
NCT ID
NCT04576988About Sotatercept + Placebo + Background PAH Therapy
Sotatercept + Placebo + Background PAH Therapy is a phase 3 stage product being developed by Merck for Pulmonary Arterial Hypertension. The current trial status is completed. This product is registered under clinical trial identifier NCT04576988. Target conditions include Pulmonary Arterial Hypertension.
Hype Score Breakdown
Clinical
27
Activity
18
Company
10
Novelty
9
Community
10
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT04576988 | Phase 3 | Completed |
Competing Products
20 competing products in Pulmonary Arterial Hypertension